Swiss National Bank Inhibrx, Inc. Transaction History

Swiss National Bank

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 07, 2024	BUY	$32.76 - $39.56 $108,108 - $130,548	3,300 Added 8.53%	42,000 $1.47 Million
Q4 2023 Feb 06, 2024	SELL	$14.5 - $38.0 $274,050 - $718,200	-18,900 Reduced 32.81%	38,700 $1.47 Million
Q3 2023 Nov 08, 2023	BUY	$15.75 - $26.31 $18,900 - $31,572	1,200 Added 2.13%	57,600 $1.06 Million
Q1 2023 May 10, 2023	SELL	$18.45 - $27.14 $3,690 - $5,428	-200 Reduced 0.35%	56,400 $1.06 Million
Q4 2022 Feb 08, 2023	BUY	$20.18 - $33.33 $22,198 - $36,663	1,100 Added 1.98%	56,600 $1.39 Million
Q3 2022 Nov 09, 2022	BUY	$11.58 - $24.73 $22,002 - $46,987	1,900 Added 3.54%	55,500 $996,000
Q2 2022 Aug 09, 2022	BUY	$8.52 - $25.26 $264,972 - $785,586	31,100 Added 138.22%	53,600 $608,000
Q1 2022 May 09, 2022	BUY	$19.89 - $43.18 $23,868 - $51,816	1,200 Added 5.63%	22,500 $501,000
Q4 2020 Feb 05, 2021	BUY	$15.96 - $50.0 $339,948 - $1.07 Million	21,300 New	21,300 $702,000

18.6K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $570M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.